newsfilter
← Latest News
Business Wire·

Guardant Health Introduces New Epigenomic Applications Providing Deeper Insights for Treatment Selection with Guardant360® Liquid

GH
  • Guardant Health announced expanded capabilities for Guardant360® Liquid powered by InfinityAI to inform therapy selection in breast & lung cancers.
  • The new features include five key advances: two novel epigenomic predictors for SERD use in advanced breast cancer & ICI monotherapy in advanced NSCLC.
  • Epigenomic identification allows for PD-L1 negative status assessment in NSCLC without requiring a tissue sample.
  • New epigenomic features identify 20-45% of ALK fusions & over 250% more MTAP deletions missed by genomic testing alone.
  • Applications aim to inform SERD treatment decisions for hormone receptor-positive, HER2-negative breast cancer patients progressing on first-line therapy.
  • The platform assesses immunotherapy response in advanced lung cancer by combining epigenomic microenvironment characterization with TMB & microsatellite instability.
  • Blood-based PD-L1 assessment is enabled to help identify NSCLC patients who may benefit from chemotherapy in addition to immunotherapy.
  • MTAP deletion evaluation supports the use of PRMT5 & MAT2A inhibitors to inform clinical trial enrollment in advanced lung cancer.
  • Guardant Health's InfinityAI platform utilizes genome-wide methylation coverage to uncover tumor biology signals for more individualized treatment decisions.